Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
Artivion, Inc. is a cardiac and vascular surgery company focused on treating aortic disease through medical devices and implantable human tissues. It operates in two segments: Medical Devices (aortic stent grafts, On‑X mechanical heart valves, surgical sealants, synthetic grafts, other devices) and Preservation Services (cardiac and vascular tissue preservation).
The company markets globally across North America, EMEA, APAC, and Latin America, using direct sales teams and distributors, and relies on organ procurement organizations and tissue banks for human tissues. It faces intense competition from large device makers and other tissue processors, as well as regulatory, quality, and supply‑chain risks, including dependence on single‑ and sole‑source suppliers and evolving US, European, UK, Swiss, and other regulatory regimes.
Artivion invests heavily in innovation, spending about $31.0 million on research and development in 2025, or roughly 7% of revenue, to advance new aortic stent graft systems, expand indications and geographies for existing products like On‑X valves and BioGlue, and support clinical trials for products such as AMDS and the NEXUS family.
Nomura Asset Management International Inc. and Nomura Investment Management Business Trust report beneficial ownership of 2,613,471 shares of Artivion, Inc. common stock on a Schedule 13G as of 12/31/2025. This represents 5.5% of the common stock, based on 47,374,939 shares outstanding as of October 31, 2025.
The firms report shared voting and dispositive power over all 2,613,471 shares, with no sole voting or dispositive power. They certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Artivion.
Artivion Inc. received an updated Schedule 13G/A (Amendment No. 7) from Macquarie Group Limited, Macquarie Management Holdings Inc., and Macquarie Investment Management Business Trust regarding Artivion’s common shares. As of 12/31/2025, the Macquarie reporting entities disclose beneficial ownership of 0 common shares, representing 0.00% of the class, with no sole or shared voting or dispositive power. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Artivion.
Artivion, Inc. reported strong growth for the fourth quarter and full year 2025, moving from losses to profitability. Fourth quarter GAAP revenue rose to $116.0 million from $97.3 million, with GAAP net income of $2.4 million versus a prior-year net loss of $(16.5) million. Full year 2025 revenue increased to $441.3 million from $388.5 million, and GAAP net income improved to $9.8 million from a net loss of $(13.4) million. Non-GAAP net income reached $8.6 million in the quarter and $29.7 million for the year, while adjusted EBITDA grew to $22.7 million in the quarter and $89.6 million for 2025. Growth was driven by aortic stent grafts, On-X valves, and steady preservation services, supported by positive clinical data and progress on regulatory filings. For 2026, Artivion guides to revenue of $486–$504 million and adjusted EBITDA of $105–$110 million, implying double‑digit revenue growth and faster adjusted EBITDA growth.
Artivion, Inc.'s Chief Commercial Officer reported selling company stock in an insider transaction. On 12/15/2025, John E. Davis sold 5,000 shares of Artivion common stock at $45.11 per share, as reflected in a regulatory report.
After this sale, Davis beneficially owned 193,842 Artivion shares, all held directly. The report was filed by him as a single reporting person in his role as Chief Commercial Officer.
John E. Davis submitted a notice of proposed sale of 5000 shares of the issuer’s common stock through broker Charles Schwab, with an approximate sale date of 12/15/2025. The shares have an aggregate market value of 225553.67 as reported in the notice and are listed on the NYSE.
The notice states that 47374939 common shares were outstanding, which helps put the planned sale in context. Davis originally acquired 10000 common shares from the issuer in a purchase on 09/16/2020, with payment made on the same date. By signing, the seller represents that he is not aware of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Artivion, Inc. insider Form 4 details a routine tax-related stock sale. The company’s Vice President and Chief Accounting Officer reported selling 4,572 shares of Artivion common stock on 12/08/2025 at a price of $44.419 per share. After this transaction, the officer beneficially owned 130,058 shares directly.
The filing explains that the shares were sold automatically upon the vesting of restricted stock units to cover tax withholding obligations through a “sell to cover” transaction, meaning it was not a discretionary open-market trade by the insider.